- Human Health
- Immune Health
Children: Stimulation of the immune system by Kluyveromyces B0399® probiotic lactic yeast in the Sinerga product.
Trial 210. RETROSPECTIVE OBSERVATIONAL STUDY TO INVESTIGATE SINERGA, A MULTIFACTORIAL NUTRITIONAL PRODUCT, AND BACTERIAL EXTRACTS IN THE PREVENTION OF RECURRENT RESPIRATORY INFECTIONS IN CHILDREN
INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY Vol. 27, no. 3, 455-460 (2014)
A. NIGRO1, A. NICASTRO2 and R. TRODELLA2
1Private practice, Montella, Avellino, Italy;
2Pediatric Department, San Giuseppe Moscati Hospital, Avellino, Italy
In this retrospective observational clinical study, 167 children, aged 3 to 7 years, of both sexes, with a clinical history of recurrent respiratory infections, administered with bacterial extracts of first and second generation or Sinerga a nutritional product containing palmitoylethanolamide, bovine colostrum, phenylethylamine and the new generation of probiotic kluyveromyces FM B0399, were observed. The goal of the study was to compare the supplementation with Sinerga with the supplementation with bacterial extracts, for the effect on the frequency of episodes of respiratory infection that had resulted in a prescription for antibiotics. The study focused retrospectively on the months from March 2013 to November 2012. The results showed a greater reduction in the frequency of respiratory infections with antibiotic therapy in the group of children supplemented with Sinerga than in the group treated with bacterial extracts. In particular, it was observed that 49.3% of the children supplemented with Sinerga, against 5% of those supplemented with extracts, had no infectious episodes requiring the administration of an antibiotic. 100% of subjects supplemented with Sinerga have had no more than two episodes of respiratory infection, while this condition, in the cohort treated with bacterial extracts, was observed in 51% of the cases.